Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy-Reference-Cited by-同舟云学术

Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy

Published:2022-12-27 Issue:4 Volume:30 Page:2458-2468
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Takaichi Shohei,Tomimaru Yoshito,Kobayashi Shogo^ORCID,Toya Keisuke,Sasaki Kazuki,Iwagami Yoshifumi,Yamada Daisaku,Noda Takehiro,Takahashi Hidenori,Asaoka Tadafumi,Tanemura Masahiro,Doki Yuichiro,Eguchi Hidetoshi

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-12985-0.pdf

Reference39 articles.

1. Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2021;5(1):7–23. https://doi.org/10.1002/ags3.12379.

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.

3. Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154–62. https://doi.org/10.1097/SLA.0000000000002734.

4. Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515–22. https://doi.org/10.1200/jco.2016.68.5081.

5. Okano K, Suto H, Oshima M, et al. A prospective phase ii trial of neoadjuvant s-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2017;24(9):2777–84. https://doi.org/10.1245/s10434-017-5921-4.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy;Pancreatology;2024-09

2. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection;Annals of Surgical Oncology;2024-08-09

3. The survival prediction of advanced colorectal cancer received neoadjuvant therapy—a study of SEER database;World Journal of Surgical Oncology;2024-07-01

4. Digital health and medical technology for perioperative sarcopenia optimisation and prehabilitation – Where to go from here?;European Journal of Surgical Oncology;2024-07

5. Role of Body Composition in Patients with Resectable Pancreatic Cancer;Nutrients;2024-06-11